SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Trinity Biotech (TRIBY) -- Ignore unavailable to you. Want to Upgrade?


To: Frederick Langford who wrote (9531)6/26/1998 5:06:00 PM
From: dowman  Read Replies (3) | Respond to of 14328
 
Here is a different way of looking at it. The only way the stock got as high as 2 3/4 was on a somewhat phony announcement about management "buying" stock. My guess is that stock was more likely sold on the spike up. As there has been no legitimate disclosure by management about this stock transaction (i.e when they bought, under what terms, and what are the governing regulations for insider trades by company officials in some kind of disclosure document). In over twenty years of doing this I have never seen a company make a press release about an insider purchase. Under U.S laws these are disclosed in SEC filings. I have also never seen a company that refuses totally to disclose or even hint at sales by product line. This silence does not help shareholders nor credibility.

As to the huge number of posts here? Have you ever seen a dog chase it's own tail?



To: Frederick Langford who wrote (9531)6/27/1998 3:24:00 PM
From: Scott H. Davis  Read Replies (1) | Respond to of 14328
 
Fredrick, two key reasons are the 30% extra shares issues/allocated year over year, and the delay of the long hoped for FDA approval of the HIV test. Watch the share count. If stable till at least qtr 1 99, revenue continues to rise, could be a big winner. Not till then tho without a big catalyst. IMSCO Scott